In 1996 was created KBI Biopharma, which is appeared as Corporate Investor. The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the Durham.
Among the most popular fund investment industries, there are Life Science, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Aeglea BioTherapeutics. Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund.
The fund is constantly included in less than 2 investment rounds annually. The top amount of exits for fund were in 2016. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 5 - 10 millions dollars.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the KBI Biopharma, startups are often financed by JSR Corp. The meaningful sponsors for the fund in investment in the same round are UT Horizon Fund, Phoenix Venture Partners LLC, Oregon Venture Fund. In the next rounds fund is usually obtained by Venrock, UT Horizon Fund, Phoenix Venture Partners LLC.
Related Funds
Fund Name | Location |
Benevolent Capital | California, Pacific Palisades, United States |
Blippar | England, London, United Kingdom |
Duro Ventures | - |
East Chain Co. | Cayman Islands, Midland |
Ecotechnologies Fund | - |
Four Acres Venture Capital | - |
Gramercy Ventures | California, San Francisco, United States |
Hui Capital | - |
JG Summit Holdings | Manila, Philippines |
Kirin Holdings | Chiyoda, Japan |
Mediacorp Singapore | Central, Central Region, Singapore |
Merapar | Netherlands, Noord-Brabant, North Brabant |
Pratithi Investment Trust | India, Maharashtra, Mumbai |
Qingdao Metro Financial Holdings | China, Qingdao, Shandong |
Quantum Energy Partners | Houston, Texas, United States |
TLSK Capital, LP. | - |
University of Maryland | College Park, Maryland, United States |
Venture Financial Management | Reston, United States, Virginia |
WENVEST Capital | Bayern, Germany, Munich |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
GlycoSeLect | $531K | 24 Oct 2017 | Dublin, County Dublin, Ireland | ||
Aeglea BioTherapeutics | $12M | 06 Feb 2014 | Austin, Texas, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
GlycoSeLect | $531K | 24 Oct 2017 | Dublin, County Dublin, Ireland | ||
Aeglea BioTherapeutics | $12M | 06 Feb 2014 | Austin, Texas, United States |